donutspug personal page - To The Moon

donutspug

No personal profile

3Follow

0Followers

0Topic

0Badge

2021-06-15

Nice

Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™

2021-06-14

Oh no!

Philips recalls some 3-4 million "CPAP", ventilator machines due to foam part

2021-06-16

Nice

New UiPath Report Finds Growing Diversity and Near 100% Job Satisfaction Among RPA Professionals

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3575240102079401","uuid":"3575240102079401","gmtCreate":1612147637123,"gmtModify":1612147637123,"name":"donutspug","pinyin":"donutspug","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":3,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.12.11","exceedPercentage":"60.37%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.10","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.31","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":169730627,"gmtCreate":1623850490469,"gmtModify":1703821342711,"author":{"id":"3575240102079401","authorId":"3575240102079401","name":"donutspug","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575240102079401","authorIdStr":"3575240102079401"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/169730627","repostId":"2143799148","repostType":4,"repost":{"id":"2143799148","kind":"news","pubTimestamp":1623845700,"share":"https://ttm.financial/m/news/2143799148?lang=&edition=fundamental","pubTime":"2021-06-16 20:15","market":"us","language":"en","title":"New UiPath Report Finds Growing Diversity and Near 100% Job Satisfaction Among RPA Professionals","url":"https://stock-news.laohu8.com/highlight/detail?id=2143799148","media":"Business Wire","summary":"Automation industry gaining momentum as 82% of students who have taken RPA courses are considering e","content":"<p><i>Automation industry gaining momentum as 82% of students who have taken RPA courses are considering entering the field full-time, according to the State of the RPA Developer Report 2021</i></p>\n<p><b>NEW YORK, Jun 16, 2021</b>--(BUSINESS WIRE)--Today at <a href=\"https://laohu8.com/S/PATH\">UiPath</a> DevCon,<b> </b>leading enterprise automation software company UiPath, Inc. (NYSE: PATH) unveiled its State of the RPA Developer Report 2021 which highlights the rapid growth of robotic process automation (RPA) careers and reveals how RPA developers feel about their future and the impact of automation on society.</p>\n<p>The survey found 97% of RPA professionals are satisfied in their careers. Of these, 63% report they are \"very satisfied,\" which is up from 51% last year—signaling that RPA developers are engaged in their work despite business disruptions over the past year. Eighty-seven percent also believe RPA will have a positive impact on society.</p>\n<p>The State of the RPA Developer Report 2021 surveyed more than 1,000 RPA developers from around the world in April 2021. Other key findings include:</p>\n<ul>\n <li><b>RPA is a fast-growing and desirable field that is relatively easy to transition into. </b>The survey found that 92% of RPA professionals think the RPA industry has a high potential for growth over the next five years. Industry hiring remains hot as 77% expect their organization to hire more RPA developers in the next 12 months, up from 70% last year. While 35% of respondents said RPA is their first professional role, RPA is not only attracting new talent to the workforce. <a href=\"https://laohu8.com/S/TWOA.U\">Two</a>-thirds of RPA developers enter from other software development roles, and 21% were formerly business analysts. Half of RPA developers said it was easy to transition into their roles.</li>\n <li><b>RPA is a diverse software development field. </b>86% of RPA professionals think RPA is more diverse or at least as diverse compared to other software development fields. There are signs of improved gender and age diversity: 20% of the RPA professionals who responded are women and half of respondents are over age 30. Promisingly, in a selection of students surveyed for the first time this year, 82% are considering a job in RPA after they graduate, citing interest in the technology and their belief that it is meaningful work.</li>\n <li><b>While developers want to stay in the field, many are looking for new jobs or are open to new opportunities. </b>Eighty percent of RPA professionals are looking for new jobs or report being open to new opportunities, though most of these job seekers (75%) want to stay in the field. The top reasons they are looking to make a change include the desire to advance their career (78%), increase their salary (78%), and learn new skills (76%).</li>\n <li><b>Like many others, RPA professionals shifted how they worked this year. </b>Eighty-five percent of respondents started working from home, and most are still doing so (as of April 2021). While 90% of RPA developers want to continue working from home at least some of the time, those who are new to remote work have faced challenges, including difficulty unplugging (47%) and collaboration (46%).</li>\n</ul>\n<p>\"Automation is awakening tremendous potential for businesses to better serve customers and to become more agile and resilient, which is expanding an entire job category to people from all backgrounds and skill levels,\" said Tom Clancy, Senior Vice President, UiPath Learning. \"It’s exciting to see both more diversity and fulfilling careers in automation blossoming. We are committed to empowering all who want to acquire RPA skills to succeed in the workplace of the future through free educational resources, training programs, and community events like UiPath DevCon.\"</p>\n<p>To learn more about the survey findings and trends, register here to join the UiPath DevCon virtual session on \"The State of the RPA Developer 2021\" on June 16 from 1–1:30 pm ET. The report is also available to download here. Join the UiPath Community to sign up for free RPA courses, view our new job board, and network with peers.</p>\n<p><b>About UiPath</b></p>\n<p>UiPath has a vision to deliver the Fully Automated Enterprise™, <a href=\"https://laohu8.com/S/AONE\">one</a> where companies use automation to unlock their greatest potential. UiPath offers an end-to-end platform for automation, combining the leading Robotic Process Automation (RPA) solution with a full suite of capabilities that enable every organization to rapidly scale digital business operations.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New UiPath Report Finds Growing Diversity and Near 100% Job Satisfaction Among RPA Professionals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew UiPath Report Finds Growing Diversity and Near 100% Job Satisfaction Among RPA Professionals\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 20:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/uipath-report-finds-growing-diversity-120000523.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Automation industry gaining momentum as 82% of students who have taken RPA courses are considering entering the field full-time, according to the State of the RPA Developer Report 2021\nNEW YORK, Jun ...</p>\n\n<a href=\"https://finance.yahoo.com/news/uipath-report-finds-growing-diversity-120000523.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PATH":"UiPath","NGD":"New Gold"},"source_url":"https://finance.yahoo.com/news/uipath-report-finds-growing-diversity-120000523.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143799148","content_text":"Automation industry gaining momentum as 82% of students who have taken RPA courses are considering entering the field full-time, according to the State of the RPA Developer Report 2021\nNEW YORK, Jun 16, 2021--(BUSINESS WIRE)--Today at UiPath DevCon, leading enterprise automation software company UiPath, Inc. (NYSE: PATH) unveiled its State of the RPA Developer Report 2021 which highlights the rapid growth of robotic process automation (RPA) careers and reveals how RPA developers feel about their future and the impact of automation on society.\nThe survey found 97% of RPA professionals are satisfied in their careers. Of these, 63% report they are \"very satisfied,\" which is up from 51% last year—signaling that RPA developers are engaged in their work despite business disruptions over the past year. Eighty-seven percent also believe RPA will have a positive impact on society.\nThe State of the RPA Developer Report 2021 surveyed more than 1,000 RPA developers from around the world in April 2021. Other key findings include:\n\nRPA is a fast-growing and desirable field that is relatively easy to transition into. The survey found that 92% of RPA professionals think the RPA industry has a high potential for growth over the next five years. Industry hiring remains hot as 77% expect their organization to hire more RPA developers in the next 12 months, up from 70% last year. While 35% of respondents said RPA is their first professional role, RPA is not only attracting new talent to the workforce. Two-thirds of RPA developers enter from other software development roles, and 21% were formerly business analysts. Half of RPA developers said it was easy to transition into their roles.\nRPA is a diverse software development field. 86% of RPA professionals think RPA is more diverse or at least as diverse compared to other software development fields. There are signs of improved gender and age diversity: 20% of the RPA professionals who responded are women and half of respondents are over age 30. Promisingly, in a selection of students surveyed for the first time this year, 82% are considering a job in RPA after they graduate, citing interest in the technology and their belief that it is meaningful work.\nWhile developers want to stay in the field, many are looking for new jobs or are open to new opportunities. Eighty percent of RPA professionals are looking for new jobs or report being open to new opportunities, though most of these job seekers (75%) want to stay in the field. The top reasons they are looking to make a change include the desire to advance their career (78%), increase their salary (78%), and learn new skills (76%).\nLike many others, RPA professionals shifted how they worked this year. Eighty-five percent of respondents started working from home, and most are still doing so (as of April 2021). While 90% of RPA developers want to continue working from home at least some of the time, those who are new to remote work have faced challenges, including difficulty unplugging (47%) and collaboration (46%).\n\n\"Automation is awakening tremendous potential for businesses to better serve customers and to become more agile and resilient, which is expanding an entire job category to people from all backgrounds and skill levels,\" said Tom Clancy, Senior Vice President, UiPath Learning. \"It’s exciting to see both more diversity and fulfilling careers in automation blossoming. We are committed to empowering all who want to acquire RPA skills to succeed in the workplace of the future through free educational resources, training programs, and community events like UiPath DevCon.\"\nTo learn more about the survey findings and trends, register here to join the UiPath DevCon virtual session on \"The State of the RPA Developer 2021\" on June 16 from 1–1:30 pm ET. The report is also available to download here. Join the UiPath Community to sign up for free RPA courses, view our new job board, and network with peers.\nAbout UiPath\nUiPath has a vision to deliver the Fully Automated Enterprise™, one where companies use automation to unlock their greatest potential. UiPath offers an end-to-end platform for automation, combining the leading Robotic Process Automation (RPA) solution with a full suite of capabilities that enable every organization to rapidly scale digital business operations.","news_type":1},"isVote":1,"tweetType":1,"viewCount":210,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187504318,"gmtCreate":1623757611434,"gmtModify":1703818289113,"author":{"id":"3575240102079401","authorId":"3575240102079401","name":"donutspug","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575240102079401","authorIdStr":"3575240102079401"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187504318","repostId":"1178091722","repostType":4,"repost":{"id":"1178091722","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1623757022,"share":"https://ttm.financial/m/news/1178091722?lang=&edition=fundamental","pubTime":"2021-06-15 19:37","market":"us","language":"en","title":"Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™","url":"https://stock-news.laohu8.com/highlight/detail?id=1178091722","media":"Tiger Newspress","summary":"Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and comm","content":"<p></p>\n<p><img src=\"https://static.tigerbbs.com/30195a620eedea62e516df9d39d4d93b\" tg-width=\"663\" tg-height=\"440\">Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner forCOVAXIN™to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets.</p>\n<p>“We are fully committed to bringing COVAXIN to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants,” saidJ.P. Gabriel, Ocugen’s Senior Vice President, Manufacturing and Supply Chain. “Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat Biotech’s strong track record of developing and commercializing vaccines globally and Jubilant’s proven track record in manufacturing, we are well-prepared to transition US manufacturing of COVAXIN to our new partner.”</p>\n<p>“We are excited to expand our basket of vaccine products and meet the increasing demand from our customers for COVID-19 vaccines in the US,” said Amit Arora, President Jubilant HollisterStier.</p>\n<p>“We are pleased to partner with Ocugen and support the ongoing fight against COVID-19. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic,” stated Pramod Yadav, CEO Jubilant Pharma Limited.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-15 19:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p></p>\n<p><img src=\"https://static.tigerbbs.com/30195a620eedea62e516df9d39d4d93b\" tg-width=\"663\" tg-height=\"440\">Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner forCOVAXIN™to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets.</p>\n<p>“We are fully committed to bringing COVAXIN to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants,” saidJ.P. Gabriel, Ocugen’s Senior Vice President, Manufacturing and Supply Chain. “Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat Biotech’s strong track record of developing and commercializing vaccines globally and Jubilant’s proven track record in manufacturing, we are well-prepared to transition US manufacturing of COVAXIN to our new partner.”</p>\n<p>“We are excited to expand our basket of vaccine products and meet the increasing demand from our customers for COVID-19 vaccines in the US,” said Amit Arora, President Jubilant HollisterStier.</p>\n<p>“We are pleased to partner with Ocugen and support the ongoing fight against COVID-19. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic,” stated Pramod Yadav, CEO Jubilant Pharma Limited.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178091722","content_text":"Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner forCOVAXIN™to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets.\n“We are fully committed to bringing COVAXIN to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants,” saidJ.P. Gabriel, Ocugen’s Senior Vice President, Manufacturing and Supply Chain. “Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat Biotech’s strong track record of developing and commercializing vaccines globally and Jubilant’s proven track record in manufacturing, we are well-prepared to transition US manufacturing of COVAXIN to our new partner.”\n“We are excited to expand our basket of vaccine products and meet the increasing demand from our customers for COVID-19 vaccines in the US,” said Amit Arora, President Jubilant HollisterStier.\n“We are pleased to partner with Ocugen and support the ongoing fight against COVID-19. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic,” stated Pramod Yadav, CEO Jubilant Pharma Limited.","news_type":1},"isVote":1,"tweetType":1,"viewCount":351,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185250918,"gmtCreate":1623655617534,"gmtModify":1704207918709,"author":{"id":"3575240102079401","authorId":"3575240102079401","name":"donutspug","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575240102079401","authorIdStr":"3575240102079401"},"themes":[],"htmlText":"Oh no!","listText":"Oh no!","text":"Oh no!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/185250918","repostId":"2143789794","repostType":4,"repost":{"id":"2143789794","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623652879,"share":"https://ttm.financial/m/news/2143789794?lang=&edition=fundamental","pubTime":"2021-06-14 14:41","market":"us","language":"en","title":"Philips recalls some 3-4 million \"CPAP\", ventilator machines due to foam part","url":"https://stock-news.laohu8.com/highlight/detail?id=2143789794","media":"Reuters","summary":"AMSTERDAM (Reuters) - Philips, the Dutch medical equipment company, on Monday said it would recall v","content":"<p>AMSTERDAM (Reuters) - Philips, the Dutch medical equipment company, on Monday said it would recall ventilators and \"CPAP\" breathing devices globally because of a foam part that might degrade and be inhaled.</p>\n<p>The company said that though the matter would cause \"revenue headwinds\" in its sleep &amp; respiratory care division, that would be compensated by strength in other businesses. It left its full year financial guidance of \"low-to-mid-single-digit\" comparable sales growth unchanged.</p>\n<p>Philips had first disclosed the issue, for which it then took a 250 million euro ($303 million) charge, in its first quarter-earnings report in April.</p>\n<p>The company's guidance is for users of the CPAP machines, which help people with sleep apnea, to halt usage. Doctors with patients using life-sustaining ventilators should first consider whether the potential danger from the foam outweighs other risks.</p>\n<p>The degrading foam, which is used to dampen the machines' sound, can turn into small, inhaled particles, irritating airways and potentially causing cancer, Philips said. Gasses released by the degrading foam may also be toxic or carry cancer risks.</p>\n<p>Philips spokesman Steve Klink said the company was working with health authorities on a safe replacement for the foam, but the new material must first clear testing and regulatory hurdles.</p>\n<p>\"Philips aims to address all affected devices\" as soon as possible, the company said in a statement.</p>\n<p>In April, Philips said first quarter core earnings surged 74% in the first quarter to 362 million euros ($438 million), compared with the same period a year earlier, on a 9% rise in comparable sales.</p>\n<p>Shares closed at 46.38 euros on Friday, up 1.6% in the year to date.</p>\n<p>($1 = 0.8263 euros)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Philips recalls some 3-4 million \"CPAP\", ventilator machines due to foam part</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPhilips recalls some 3-4 million \"CPAP\", ventilator machines due to foam part\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-14 14:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AMSTERDAM (Reuters) - Philips, the Dutch medical equipment company, on Monday said it would recall ventilators and \"CPAP\" breathing devices globally because of a foam part that might degrade and be inhaled.</p>\n<p>The company said that though the matter would cause \"revenue headwinds\" in its sleep &amp; respiratory care division, that would be compensated by strength in other businesses. It left its full year financial guidance of \"low-to-mid-single-digit\" comparable sales growth unchanged.</p>\n<p>Philips had first disclosed the issue, for which it then took a 250 million euro ($303 million) charge, in its first quarter-earnings report in April.</p>\n<p>The company's guidance is for users of the CPAP machines, which help people with sleep apnea, to halt usage. Doctors with patients using life-sustaining ventilators should first consider whether the potential danger from the foam outweighs other risks.</p>\n<p>The degrading foam, which is used to dampen the machines' sound, can turn into small, inhaled particles, irritating airways and potentially causing cancer, Philips said. Gasses released by the degrading foam may also be toxic or carry cancer risks.</p>\n<p>Philips spokesman Steve Klink said the company was working with health authorities on a safe replacement for the foam, but the new material must first clear testing and regulatory hurdles.</p>\n<p>\"Philips aims to address all affected devices\" as soon as possible, the company said in a statement.</p>\n<p>In April, Philips said first quarter core earnings surged 74% in the first quarter to 362 million euros ($438 million), compared with the same period a year earlier, on a 9% rise in comparable sales.</p>\n<p>Shares closed at 46.38 euros on Friday, up 1.6% in the year to date.</p>\n<p>($1 = 0.8263 euros)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"0LNG.UK":"飞利浦","PHG":"飞利浦"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143789794","content_text":"AMSTERDAM (Reuters) - Philips, the Dutch medical equipment company, on Monday said it would recall ventilators and \"CPAP\" breathing devices globally because of a foam part that might degrade and be inhaled.\nThe company said that though the matter would cause \"revenue headwinds\" in its sleep & respiratory care division, that would be compensated by strength in other businesses. It left its full year financial guidance of \"low-to-mid-single-digit\" comparable sales growth unchanged.\nPhilips had first disclosed the issue, for which it then took a 250 million euro ($303 million) charge, in its first quarter-earnings report in April.\nThe company's guidance is for users of the CPAP machines, which help people with sleep apnea, to halt usage. Doctors with patients using life-sustaining ventilators should first consider whether the potential danger from the foam outweighs other risks.\nThe degrading foam, which is used to dampen the machines' sound, can turn into small, inhaled particles, irritating airways and potentially causing cancer, Philips said. Gasses released by the degrading foam may also be toxic or carry cancer risks.\nPhilips spokesman Steve Klink said the company was working with health authorities on a safe replacement for the foam, but the new material must first clear testing and regulatory hurdles.\n\"Philips aims to address all affected devices\" as soon as possible, the company said in a statement.\nIn April, Philips said first quarter core earnings surged 74% in the first quarter to 362 million euros ($438 million), compared with the same period a year earlier, on a 9% rise in comparable sales.\nShares closed at 46.38 euros on Friday, up 1.6% in the year to date.\n($1 = 0.8263 euros)","news_type":1},"isVote":1,"tweetType":1,"viewCount":268,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":187504318,"gmtCreate":1623757611434,"gmtModify":1703818289113,"author":{"id":"3575240102079401","authorId":"3575240102079401","name":"donutspug","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575240102079401","authorIdStr":"3575240102079401"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187504318","repostId":"1178091722","repostType":4,"repost":{"id":"1178091722","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1623757022,"share":"https://ttm.financial/m/news/1178091722?lang=&edition=fundamental","pubTime":"2021-06-15 19:37","market":"us","language":"en","title":"Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™","url":"https://stock-news.laohu8.com/highlight/detail?id=1178091722","media":"Tiger Newspress","summary":"Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and comm","content":"<p></p>\n<p><img src=\"https://static.tigerbbs.com/30195a620eedea62e516df9d39d4d93b\" tg-width=\"663\" tg-height=\"440\">Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner forCOVAXIN™to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets.</p>\n<p>“We are fully committed to bringing COVAXIN to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants,” saidJ.P. Gabriel, Ocugen’s Senior Vice President, Manufacturing and Supply Chain. “Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat Biotech’s strong track record of developing and commercializing vaccines globally and Jubilant’s proven track record in manufacturing, we are well-prepared to transition US manufacturing of COVAXIN to our new partner.”</p>\n<p>“We are excited to expand our basket of vaccine products and meet the increasing demand from our customers for COVID-19 vaccines in the US,” said Amit Arora, President Jubilant HollisterStier.</p>\n<p>“We are pleased to partner with Ocugen and support the ongoing fight against COVID-19. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic,” stated Pramod Yadav, CEO Jubilant Pharma Limited.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-15 19:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p></p>\n<p><img src=\"https://static.tigerbbs.com/30195a620eedea62e516df9d39d4d93b\" tg-width=\"663\" tg-height=\"440\">Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner forCOVAXIN™to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets.</p>\n<p>“We are fully committed to bringing COVAXIN to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants,” saidJ.P. Gabriel, Ocugen’s Senior Vice President, Manufacturing and Supply Chain. “Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat Biotech’s strong track record of developing and commercializing vaccines globally and Jubilant’s proven track record in manufacturing, we are well-prepared to transition US manufacturing of COVAXIN to our new partner.”</p>\n<p>“We are excited to expand our basket of vaccine products and meet the increasing demand from our customers for COVID-19 vaccines in the US,” said Amit Arora, President Jubilant HollisterStier.</p>\n<p>“We are pleased to partner with Ocugen and support the ongoing fight against COVID-19. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic,” stated Pramod Yadav, CEO Jubilant Pharma Limited.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178091722","content_text":"Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner forCOVAXIN™to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets.\n“We are fully committed to bringing COVAXIN to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants,” saidJ.P. Gabriel, Ocugen’s Senior Vice President, Manufacturing and Supply Chain. “Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat Biotech’s strong track record of developing and commercializing vaccines globally and Jubilant’s proven track record in manufacturing, we are well-prepared to transition US manufacturing of COVAXIN to our new partner.”\n“We are excited to expand our basket of vaccine products and meet the increasing demand from our customers for COVID-19 vaccines in the US,” said Amit Arora, President Jubilant HollisterStier.\n“We are pleased to partner with Ocugen and support the ongoing fight against COVID-19. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic,” stated Pramod Yadav, CEO Jubilant Pharma Limited.","news_type":1},"isVote":1,"tweetType":1,"viewCount":351,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185250918,"gmtCreate":1623655617534,"gmtModify":1704207918709,"author":{"id":"3575240102079401","authorId":"3575240102079401","name":"donutspug","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575240102079401","authorIdStr":"3575240102079401"},"themes":[],"htmlText":"Oh no!","listText":"Oh no!","text":"Oh no!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/185250918","repostId":"2143789794","repostType":4,"repost":{"id":"2143789794","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623652879,"share":"https://ttm.financial/m/news/2143789794?lang=&edition=fundamental","pubTime":"2021-06-14 14:41","market":"us","language":"en","title":"Philips recalls some 3-4 million \"CPAP\", ventilator machines due to foam part","url":"https://stock-news.laohu8.com/highlight/detail?id=2143789794","media":"Reuters","summary":"AMSTERDAM (Reuters) - Philips, the Dutch medical equipment company, on Monday said it would recall v","content":"<p>AMSTERDAM (Reuters) - Philips, the Dutch medical equipment company, on Monday said it would recall ventilators and \"CPAP\" breathing devices globally because of a foam part that might degrade and be inhaled.</p>\n<p>The company said that though the matter would cause \"revenue headwinds\" in its sleep &amp; respiratory care division, that would be compensated by strength in other businesses. It left its full year financial guidance of \"low-to-mid-single-digit\" comparable sales growth unchanged.</p>\n<p>Philips had first disclosed the issue, for which it then took a 250 million euro ($303 million) charge, in its first quarter-earnings report in April.</p>\n<p>The company's guidance is for users of the CPAP machines, which help people with sleep apnea, to halt usage. Doctors with patients using life-sustaining ventilators should first consider whether the potential danger from the foam outweighs other risks.</p>\n<p>The degrading foam, which is used to dampen the machines' sound, can turn into small, inhaled particles, irritating airways and potentially causing cancer, Philips said. Gasses released by the degrading foam may also be toxic or carry cancer risks.</p>\n<p>Philips spokesman Steve Klink said the company was working with health authorities on a safe replacement for the foam, but the new material must first clear testing and regulatory hurdles.</p>\n<p>\"Philips aims to address all affected devices\" as soon as possible, the company said in a statement.</p>\n<p>In April, Philips said first quarter core earnings surged 74% in the first quarter to 362 million euros ($438 million), compared with the same period a year earlier, on a 9% rise in comparable sales.</p>\n<p>Shares closed at 46.38 euros on Friday, up 1.6% in the year to date.</p>\n<p>($1 = 0.8263 euros)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Philips recalls some 3-4 million \"CPAP\", ventilator machines due to foam part</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPhilips recalls some 3-4 million \"CPAP\", ventilator machines due to foam part\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-14 14:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AMSTERDAM (Reuters) - Philips, the Dutch medical equipment company, on Monday said it would recall ventilators and \"CPAP\" breathing devices globally because of a foam part that might degrade and be inhaled.</p>\n<p>The company said that though the matter would cause \"revenue headwinds\" in its sleep &amp; respiratory care division, that would be compensated by strength in other businesses. It left its full year financial guidance of \"low-to-mid-single-digit\" comparable sales growth unchanged.</p>\n<p>Philips had first disclosed the issue, for which it then took a 250 million euro ($303 million) charge, in its first quarter-earnings report in April.</p>\n<p>The company's guidance is for users of the CPAP machines, which help people with sleep apnea, to halt usage. Doctors with patients using life-sustaining ventilators should first consider whether the potential danger from the foam outweighs other risks.</p>\n<p>The degrading foam, which is used to dampen the machines' sound, can turn into small, inhaled particles, irritating airways and potentially causing cancer, Philips said. Gasses released by the degrading foam may also be toxic or carry cancer risks.</p>\n<p>Philips spokesman Steve Klink said the company was working with health authorities on a safe replacement for the foam, but the new material must first clear testing and regulatory hurdles.</p>\n<p>\"Philips aims to address all affected devices\" as soon as possible, the company said in a statement.</p>\n<p>In April, Philips said first quarter core earnings surged 74% in the first quarter to 362 million euros ($438 million), compared with the same period a year earlier, on a 9% rise in comparable sales.</p>\n<p>Shares closed at 46.38 euros on Friday, up 1.6% in the year to date.</p>\n<p>($1 = 0.8263 euros)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"0LNG.UK":"飞利浦","PHG":"飞利浦"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143789794","content_text":"AMSTERDAM (Reuters) - Philips, the Dutch medical equipment company, on Monday said it would recall ventilators and \"CPAP\" breathing devices globally because of a foam part that might degrade and be inhaled.\nThe company said that though the matter would cause \"revenue headwinds\" in its sleep & respiratory care division, that would be compensated by strength in other businesses. It left its full year financial guidance of \"low-to-mid-single-digit\" comparable sales growth unchanged.\nPhilips had first disclosed the issue, for which it then took a 250 million euro ($303 million) charge, in its first quarter-earnings report in April.\nThe company's guidance is for users of the CPAP machines, which help people with sleep apnea, to halt usage. Doctors with patients using life-sustaining ventilators should first consider whether the potential danger from the foam outweighs other risks.\nThe degrading foam, which is used to dampen the machines' sound, can turn into small, inhaled particles, irritating airways and potentially causing cancer, Philips said. Gasses released by the degrading foam may also be toxic or carry cancer risks.\nPhilips spokesman Steve Klink said the company was working with health authorities on a safe replacement for the foam, but the new material must first clear testing and regulatory hurdles.\n\"Philips aims to address all affected devices\" as soon as possible, the company said in a statement.\nIn April, Philips said first quarter core earnings surged 74% in the first quarter to 362 million euros ($438 million), compared with the same period a year earlier, on a 9% rise in comparable sales.\nShares closed at 46.38 euros on Friday, up 1.6% in the year to date.\n($1 = 0.8263 euros)","news_type":1},"isVote":1,"tweetType":1,"viewCount":268,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169730627,"gmtCreate":1623850490469,"gmtModify":1703821342711,"author":{"id":"3575240102079401","authorId":"3575240102079401","name":"donutspug","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575240102079401","authorIdStr":"3575240102079401"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/169730627","repostId":"2143799148","repostType":4,"repost":{"id":"2143799148","kind":"news","pubTimestamp":1623845700,"share":"https://ttm.financial/m/news/2143799148?lang=&edition=fundamental","pubTime":"2021-06-16 20:15","market":"us","language":"en","title":"New UiPath Report Finds Growing Diversity and Near 100% Job Satisfaction Among RPA Professionals","url":"https://stock-news.laohu8.com/highlight/detail?id=2143799148","media":"Business Wire","summary":"Automation industry gaining momentum as 82% of students who have taken RPA courses are considering e","content":"<p><i>Automation industry gaining momentum as 82% of students who have taken RPA courses are considering entering the field full-time, according to the State of the RPA Developer Report 2021</i></p>\n<p><b>NEW YORK, Jun 16, 2021</b>--(BUSINESS WIRE)--Today at <a href=\"https://laohu8.com/S/PATH\">UiPath</a> DevCon,<b> </b>leading enterprise automation software company UiPath, Inc. (NYSE: PATH) unveiled its State of the RPA Developer Report 2021 which highlights the rapid growth of robotic process automation (RPA) careers and reveals how RPA developers feel about their future and the impact of automation on society.</p>\n<p>The survey found 97% of RPA professionals are satisfied in their careers. Of these, 63% report they are \"very satisfied,\" which is up from 51% last year—signaling that RPA developers are engaged in their work despite business disruptions over the past year. Eighty-seven percent also believe RPA will have a positive impact on society.</p>\n<p>The State of the RPA Developer Report 2021 surveyed more than 1,000 RPA developers from around the world in April 2021. Other key findings include:</p>\n<ul>\n <li><b>RPA is a fast-growing and desirable field that is relatively easy to transition into. </b>The survey found that 92% of RPA professionals think the RPA industry has a high potential for growth over the next five years. Industry hiring remains hot as 77% expect their organization to hire more RPA developers in the next 12 months, up from 70% last year. While 35% of respondents said RPA is their first professional role, RPA is not only attracting new talent to the workforce. <a href=\"https://laohu8.com/S/TWOA.U\">Two</a>-thirds of RPA developers enter from other software development roles, and 21% were formerly business analysts. Half of RPA developers said it was easy to transition into their roles.</li>\n <li><b>RPA is a diverse software development field. </b>86% of RPA professionals think RPA is more diverse or at least as diverse compared to other software development fields. There are signs of improved gender and age diversity: 20% of the RPA professionals who responded are women and half of respondents are over age 30. Promisingly, in a selection of students surveyed for the first time this year, 82% are considering a job in RPA after they graduate, citing interest in the technology and their belief that it is meaningful work.</li>\n <li><b>While developers want to stay in the field, many are looking for new jobs or are open to new opportunities. </b>Eighty percent of RPA professionals are looking for new jobs or report being open to new opportunities, though most of these job seekers (75%) want to stay in the field. The top reasons they are looking to make a change include the desire to advance their career (78%), increase their salary (78%), and learn new skills (76%).</li>\n <li><b>Like many others, RPA professionals shifted how they worked this year. </b>Eighty-five percent of respondents started working from home, and most are still doing so (as of April 2021). While 90% of RPA developers want to continue working from home at least some of the time, those who are new to remote work have faced challenges, including difficulty unplugging (47%) and collaboration (46%).</li>\n</ul>\n<p>\"Automation is awakening tremendous potential for businesses to better serve customers and to become more agile and resilient, which is expanding an entire job category to people from all backgrounds and skill levels,\" said Tom Clancy, Senior Vice President, UiPath Learning. \"It’s exciting to see both more diversity and fulfilling careers in automation blossoming. We are committed to empowering all who want to acquire RPA skills to succeed in the workplace of the future through free educational resources, training programs, and community events like UiPath DevCon.\"</p>\n<p>To learn more about the survey findings and trends, register here to join the UiPath DevCon virtual session on \"The State of the RPA Developer 2021\" on June 16 from 1–1:30 pm ET. The report is also available to download here. Join the UiPath Community to sign up for free RPA courses, view our new job board, and network with peers.</p>\n<p><b>About UiPath</b></p>\n<p>UiPath has a vision to deliver the Fully Automated Enterprise™, <a href=\"https://laohu8.com/S/AONE\">one</a> where companies use automation to unlock their greatest potential. UiPath offers an end-to-end platform for automation, combining the leading Robotic Process Automation (RPA) solution with a full suite of capabilities that enable every organization to rapidly scale digital business operations.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New UiPath Report Finds Growing Diversity and Near 100% Job Satisfaction Among RPA Professionals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew UiPath Report Finds Growing Diversity and Near 100% Job Satisfaction Among RPA Professionals\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 20:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/uipath-report-finds-growing-diversity-120000523.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Automation industry gaining momentum as 82% of students who have taken RPA courses are considering entering the field full-time, according to the State of the RPA Developer Report 2021\nNEW YORK, Jun ...</p>\n\n<a href=\"https://finance.yahoo.com/news/uipath-report-finds-growing-diversity-120000523.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PATH":"UiPath","NGD":"New Gold"},"source_url":"https://finance.yahoo.com/news/uipath-report-finds-growing-diversity-120000523.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143799148","content_text":"Automation industry gaining momentum as 82% of students who have taken RPA courses are considering entering the field full-time, according to the State of the RPA Developer Report 2021\nNEW YORK, Jun 16, 2021--(BUSINESS WIRE)--Today at UiPath DevCon, leading enterprise automation software company UiPath, Inc. (NYSE: PATH) unveiled its State of the RPA Developer Report 2021 which highlights the rapid growth of robotic process automation (RPA) careers and reveals how RPA developers feel about their future and the impact of automation on society.\nThe survey found 97% of RPA professionals are satisfied in their careers. Of these, 63% report they are \"very satisfied,\" which is up from 51% last year—signaling that RPA developers are engaged in their work despite business disruptions over the past year. Eighty-seven percent also believe RPA will have a positive impact on society.\nThe State of the RPA Developer Report 2021 surveyed more than 1,000 RPA developers from around the world in April 2021. Other key findings include:\n\nRPA is a fast-growing and desirable field that is relatively easy to transition into. The survey found that 92% of RPA professionals think the RPA industry has a high potential for growth over the next five years. Industry hiring remains hot as 77% expect their organization to hire more RPA developers in the next 12 months, up from 70% last year. While 35% of respondents said RPA is their first professional role, RPA is not only attracting new talent to the workforce. Two-thirds of RPA developers enter from other software development roles, and 21% were formerly business analysts. Half of RPA developers said it was easy to transition into their roles.\nRPA is a diverse software development field. 86% of RPA professionals think RPA is more diverse or at least as diverse compared to other software development fields. There are signs of improved gender and age diversity: 20% of the RPA professionals who responded are women and half of respondents are over age 30. Promisingly, in a selection of students surveyed for the first time this year, 82% are considering a job in RPA after they graduate, citing interest in the technology and their belief that it is meaningful work.\nWhile developers want to stay in the field, many are looking for new jobs or are open to new opportunities. Eighty percent of RPA professionals are looking for new jobs or report being open to new opportunities, though most of these job seekers (75%) want to stay in the field. The top reasons they are looking to make a change include the desire to advance their career (78%), increase their salary (78%), and learn new skills (76%).\nLike many others, RPA professionals shifted how they worked this year. Eighty-five percent of respondents started working from home, and most are still doing so (as of April 2021). While 90% of RPA developers want to continue working from home at least some of the time, those who are new to remote work have faced challenges, including difficulty unplugging (47%) and collaboration (46%).\n\n\"Automation is awakening tremendous potential for businesses to better serve customers and to become more agile and resilient, which is expanding an entire job category to people from all backgrounds and skill levels,\" said Tom Clancy, Senior Vice President, UiPath Learning. \"It’s exciting to see both more diversity and fulfilling careers in automation blossoming. We are committed to empowering all who want to acquire RPA skills to succeed in the workplace of the future through free educational resources, training programs, and community events like UiPath DevCon.\"\nTo learn more about the survey findings and trends, register here to join the UiPath DevCon virtual session on \"The State of the RPA Developer 2021\" on June 16 from 1–1:30 pm ET. The report is also available to download here. Join the UiPath Community to sign up for free RPA courses, view our new job board, and network with peers.\nAbout UiPath\nUiPath has a vision to deliver the Fully Automated Enterprise™, one where companies use automation to unlock their greatest potential. UiPath offers an end-to-end platform for automation, combining the leading Robotic Process Automation (RPA) solution with a full suite of capabilities that enable every organization to rapidly scale digital business operations.","news_type":1},"isVote":1,"tweetType":1,"viewCount":210,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}